hold

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

二 |      8 月 26 日消息，真我今天在印度发布了最新机型 realme P4s，目前 P4 系列已经拥有超过 6 款智能手机产品。P4s 采用三星供应的 6.77 英寸 144Hz AMOLED 屏幕，基于 M14 OLED 技术打造，覆盖 AGC DT Star D+ 玻璃，分辨率 2772×1272，峰值亮度 6500 尼特，并支持 HDR10+。屏幕还支持湿手和油手触控，手指沾水或油污时依然可以正常操作。性能方面，P4s 搭载天玑 7400 Ultra，并配备独立的 Hyper Vision+ AI 图形芯片，提升游戏体验。该机支持 90FPS 和 144FPS 游戏，屏幕可在 FPS、MOBA、体育、竞速和沙盒 5 类游戏中以 144Hz 刷新率运行。天玑 7400 Ultra 最高搭配 12GB LPDDR4X 内存，最高提供 256GB UFS 3.1 存储空间。系统出厂为基于 Android 16 的 realme UI 7.0，真我承诺提供 3 次 Android 大版本升级和 4 年安全更新。影像方面，该机配备 5000 万像素主摄、800 万像素超广角摄像头和 1600 万像素前置摄像头。主摄支持光学防抖，超广角和前置摄像头的视野分别为 112° 和 85°。

三 | 后置摄像头和 LED 闪光灯集中在采用多种纹理设计的相机区域内。AI 影像功能包括 AI Light Me、AI StyleMe 和 AI Framing Master。该机配备 8000mAh 电池，支持 80W 有线充电、反向有线充电和旁路充电。其他配置包括 7000mm² VC 均热板散热系统、双立体声扬声器，以及 IP66、IP68 和 IP69 防尘防水。

四 | 该机提供 Electric Cyan 和 Titanium Gray 两种配色，8GB+128GB、8GB+256GB 和 12GB+256GB 三个版本售价分别为 34,999 印度卢比（注：现汇率约合 2,458 元人民币）、37,999 印度卢比（现汇率约合 2,668 元人民币）和 41,999 印度卢比（现汇率约合 2,949 元人民币），9 月 3 日起在印度开售。

Current article:http://s4gu2u.cuozubeishenjingli.cfd/fmh8cb/20260826/3894.html

Published on:21:12:01